Xilio Therapeutics Inc. – Material Contracts Watch

from 8-K 3 pages Xilio Therapeutics, Inc. Amended and Restated Director Compensation Policy Effective: April 15, 2026

from 10-K 3 pages Xilio Therapeutics, Inc. Amended and Restated Director Compensation Policy Effective: December 9, 2025

from 10-K 16 pages Amended and Restated Employment Agreement

from 10-K 7 pages Xilio Therapeutics, Inc. Stock Option Agreement

from 10-K 6 pages Xilio Therapeutics, Inc. Stock Option Agreement

from 10-K 15 pages The Purpose of This Second Amended and Restated 2022 Inducement Stock Incentive Plan (The “Plan”) of Xilio Therapeutics, Inc., a Delaware Corporation (The “Company”), Is to Advance the Interests of the Company’s Stockholders by Enhancing the Company’s Ability to Attract, Retain and Motivate Persons Who Are Expected to Make Important Contributions to the Company With an Inducement Material for Such Persons to Enter Into Employment With the Company and by Providing Such Persons With Equity Ownership Opportunities and Performance-Based Incentives That Are Intended to Better Align the Interests of Such Persons With Those of the Company’s Stockholders. Except Where the Context Otherwise Requires, the Term “Company” Shall Include Any of the Company’s Present or Future Parent or Subsidiary Corporations as Defined in Sections 424(e) or (F) of the Internal Revenue Code of 1986, as Amended, and Any Regulations Thereunder (The “Code”) and Any Other Business Venture (Including, Without Limitation, Joint Venture or Limited Liability Company) in Which the Company Has a Controlling Interest, as Determined by the Board of Directors of the Company (The “Board”). 2. Eligibility

from 10-Q 20 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Xilio Therapeutics, Inc. Investor Rights Agreement

from 10-Q 27 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Xilio Therapeutics, Inc. Common Stock Purchase Agreement

from 10-Q 98 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Collaboration, License and Option Agreement by and Among Xilio Development, Inc. and Abbvie Group Holdings Limited Dated as of February 10, 2025 ​

from 10-K 14 pages Xilio Therapeutics, Inc. Amended and Restated 2022 Inducement Stock Incentive Plan

from 10-Q 13 pages Third Amended and Restated Employment Agreement

from 10-Q 2 pages Xilio Therapeutics, Inc. Amended and Restated Director Compensation Policy Effective: April 16, 2024

from 10-Q 19 pages Article 1​ ​ Definitions

from 10-Q 33 pages Article 1​ ​ Definitions

from 10-Q 76 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. License Agreement Between Xilio Development, Inc. and Gilead Sciences, Inc. Dated as of March 27, 2024 ​

from 10-K 16 pages Employment Agreement

from 8-K 23 pages Registration Rights Agreement

from 8-K 32 pages Securities Purchase Agreement

from 8-K 5 pages Xilio Therapeutics, Inc. Restricted Stock Unit Agreement Granted Under 2021 Stock Incentive Plan Incorporated Terms and Conditions

from 10-Q 11 pages Consulting Agreement